Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429811 | 0.96 | GAA (0.52) | GAAKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL11705905 | 0.94 | GAA (0.51) | GAAKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL27941396 | 0.93 | GAA (0.52) | GAAKMT2AALDH1A1LMNAHTT | |
| SCHEMBL29594097 | 0.92 | GAA (0.57) | GAAKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL2252361 | 0.92 | GAA (0.57) | GAAKMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL223804 | 0.92 | GAA (0.49) | GAAKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL28446011 | 0.91 | KMT2A (0.50) | GAAKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL11706012 | 0.88 | THRB (0.49) | GAAKMT2AALDH1A1LMNAHSD17B10 | |
| SCHEMBL11705042 | 0.87 | GAA (0.44) | GAAKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL221190 | 0.86 | MAPT (0.47) | GAAKMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8613868-B2 | Mesogenic stabilizers | TRANSITIONS OPTICAL, INC (US) | 2013-12-24 | — | — | US | disclosed |
| WO-2013022610-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20120021144-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021144-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021144-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021144-A1 | MESOGENIC STABILIZERS | C1S, C5, CCNL2 | GAA 4824/4885KMT2A 1363/4885MAPT 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.